EverHint – Dip Bounce V2 (Reclaim) – Top 10 Signals for Oct 28, 2026
Excerpt: 10 signals (from 46 total). Healthcare leads (23). price range $12-$424. 3 with insider selling.
What This Signal Is
Production-ready dip-bounce strategy using reclaim pattern with Phase 2 market regime filters. Improved win rate from 40.42% (V1) to 50.18% (V2) with VIX and record high filters.
Entry Criteria:
- Minimum dip: 3.3% (open to intraday low)
- Minimum bounce: 1.0% from low
- Net change range: -2.0% to +0.3%
- Price above SMA(200)
- Minimum ADV: $40M
Holding period: 1-5 days | Risk level: Medium
Market Context
Equity markets are trading in a steady, constructive tone on October 28, 2026, with all three major indices posting modest gains and the S&P 500 holding above 7,744. The broad-based advance — led by the Nasdaq and supported by the Dow — signals healthy risk appetite without signs of speculative excess. This measured upside environment is well-suited for dip-bounce reclaim strategies, as price action tends to be deliberate rather than erratic, giving setups room to develop and confirm before triggering.
The VIX at 16.91, down over 3% on the session, reflects a meaningful compression in near-term fear. Lower volatility reduces the likelihood of sharp intraday reversals that can prematurely stop out bounce plays, but traders should remain mindful that extremely compressed volatility can also dampen the magnitude of the anticipated recovery move. The sweet spot for dip-bounce signals tends to sit in the 15–20 VIX range, and current readings fall squarely within that window, supporting a favorable signal-to-noise ratio for the 46 setups generated today.
Healthcare's emergence as the top sector is a notable rotation signal. Defensive sector leadership alongside a rising broader market often indicates that institutional money is selectively rotating into lower-beta areas while maintaining overall equity exposure — a classic late-cycle or uncertainty-hedging posture. For dip-bounce reclaim strategies, this rotation suggests that setups within healthcare may carry stronger follow-through potential, as sector-specific demand provides a tailwind beyond general market momentum.
📊 Signals (10 of 46 total)
Ranked by dip magnitude (highest first)
| # | Ticker | Company | Sector | Price | Score | Insider | MCap |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera, Inc. | Healthcare | $424.42 | 0.30 | Sell -$68,751 | $61.2B |
| 2 | TEM | Tempus AI, Inc. | Healthcare | $76.61 | 0.21 | — | $13.6B |
| 3 | TWST | Twist Bioscience Corpo... | Healthcare | $173.45 | 0.21 | — | $11.4B |
| 4 | ABSI | Absci Corporation | Healthcare | $11.88 | 0.21 | — | $2.0B |
| 5 | SDGR | Schrödinger, Inc. | Healthcare | $30.87 | 0.21 | — | $2.3B |
| 6 | REPL | Replimune Group, Inc. | Healthcare | $16.06 | 0.21 | — | $1.5B |
| 7 | TXN | Texas Instruments Inco... | Technology | $309.83 | 0.20 | — | $283.0B |
| 8 | QCOM | QUALCOMM Incorporated | Technology | $182.97 | 0.20 | — | $195.4B |
| 9 | ABCL | AbCellera Biologics Inc. | Healthcare | $13.64 | 0.20 | — | $4.4B |
| 10 | TXG | 10x Genomics, Inc. | Healthcare | $83.62 | 0.20 | — | $10.9B |
Recent Headlines
REPL (Replimune Group, Inc.)
- Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Enjoying the updates? Liking, sharing, or subscribing helps bring this analysis to a wider audience.